Citadel Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-24,735
| Closed | -$411K | – | 6018 |
|
|
2024
Q1 | $411K | Buy |
+24,735
| New | +$411K | ﹤0.01% | 4115 |
|
|
2023
Q2 | – | Sell |
-26,011
| Closed | -$312K | – | 5885 |
|
|
2023
Q1 | $312K | Buy |
26,011
+12,390
| +91% | +$149K | ﹤0.01% | 4275 |
|
|
2022
Q4 | $187K | Sell |
13,621
-7,200
| -35% | -$98.9K | ﹤0.01% | 4733 |
|
|
2022
Q3 | $305K | Buy |
+20,821
| New | +$305K | ﹤0.01% | 4521 |
|
|
2022
Q2 | – | Sell |
-14,275
| Closed | -$257K | – | 6094 |
|
|
2022
Q1 | $257K | Buy |
+14,275
| New | +$257K | ﹤0.01% | 5078 |
|
|
2021
Q3 | – | Sell |
-46,951
| Closed | -$1.5M | – | 6444 |
|
|
2021
Q2 | $1.5M | Buy |
46,951
+4,123
| +10% | +$131K | ﹤0.01% | 3556 |
|
|
2021
Q1 | $1.28M | Buy |
42,828
+33,674
| +368% | +$1M | ﹤0.01% | 3653 |
|
|
2020
Q4 | $290K | Sell |
9,154
-15,491
| -63% | -$491K | ﹤0.01% | 4262 |
|
|
2020
Q3 | $675K | Buy |
24,645
+3,099
| +14% | +$84.9K | ﹤0.01% | 3239 |
|
|
2020
Q2 | $588K | Sell |
21,546
-1,132
| -5% | -$30.9K | ﹤0.01% | 3322 |
|
|
2020
Q1 | $450K | Sell |
22,678
-12,221
| -35% | -$243K | ﹤0.01% | 3480 |
|
|
2019
Q4 | $818K | Sell |
34,899
-5,084
| -13% | -$119K | ﹤0.01% | 3173 |
|
|
2019
Q3 | $743K | Buy |
39,983
+3,408
| +9% | +$63.3K | ﹤0.01% | 3170 |
|
|
2019
Q2 | $771K | Buy |
36,575
+2,711
| +8% | +$57.1K | ﹤0.01% | 3191 |
|
|
2019
Q1 | $712K | Buy |
+33,864
| New | +$712K | ﹤0.01% | 3107 |
|
|
2017
Q1 | – | Sell |
-12,144
| Closed | -$257K | – | 3695 |
|
|
2016
Q4 | $257K | Buy |
+12,144
| New | +$257K | ﹤0.01% | 2895 |
|
|
2016
Q2 | – | Sell |
-10,126
| Closed | -$220K | – | 3416 |
|
|
2016
Q1 | $220K | Buy |
+10,126
| New | +$220K | ﹤0.01% | 2668 |
|